We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Several recurrent and prognostic chromosome alterations have been identified in myeloma and their identification is useful in the management of these patients. These include translocations involving the FGFR3, MAF, MAFB and CCND1 genes with the IGH gene, loss of 17p13.1(P53), loss of 13q14.3, rearrangement of MYC, and hyperdiploidy. The t(14;16), t(4;14), and t(14;20) translocations involving the MAF, FGFR3, and MAFB genes, respectively, each independently identify poor prognostic groups. Deletion of 13q14.3, rearrangement of MYC, or 17p13.1(P53) are two additional poor prognostic indicators in myeloma. Hyperdiploidy is associated with a favorable prognosis and the t(11;14) portends an intermediate prognosis.
Organ: Blood/Bone Marrow
Disease State: Plasma Cell Myeloma/Neoplasm
CPT Code(s): 88374x6, 88367; 88373x5. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Turnaround Time: Within 4-6 business days of receipt
Schedule: Monday - Friday
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR - • Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR - • Fresh tissue in RPMI